Mersana Therapeutics (NASDAQ: MRSN)
Mersana Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mersana Therapeutics Company Info
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
News & Analysis
Why Mersana Therapeutics Stock Is Crashing Today
The company reported disappointing clinical results.
Got $1,000? Buy These 4 Cancer Stocks
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
Why Mersana Therapeutics Stock Is Skyrocketing Today
Investors are excited about the biotech's encouraging results from an early-stage clinical trial.
Here's Why Mersana Therapeutics Stock Is Soaring Today
The company raised more money to keep developing potential new cancer therapies.
Here's Why Mersana Therapeutics Is Sinking Today
Clinical-trial results from the company's first proof-of-concept study were disappointing.
Why Nio, Mersana Therapeutics, and Tandem Diabetes Care Slumped Today
Find out what took the energy out of these stocks.
Valuation
Earnings Transcripts
Mersana Therapeutics, Inc. (MRSN) Q1 2020 Earnings Call Transcript
MRSN earnings call for the period ending March 31, 2020.
Mersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Call Transcript
MRSN earnings call for the period ending March 31, 2019.
Mersana Therapeutics, Inc. (MRSN) Q2 2018 Earnings Conference Call Transcript
MRSN earnings call for the period ending June 30, 2018.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.